Law360, New York (December 08, 2011, 2:46 PM ET) -- The Federal Circuit on Thursday upheld a Delaware court's ruling that Watson Pharmaceuticals Inc.’s proposed generic version of Fentora infringes Cephalon Inc.’s patent for the painkiller.
The appeals court affirmed the lower court's ruling in a nonprecedential, per curiam decision that did not offer an explanation for the decision.
U.S. District Judge Sue L. Robinson held in March that Watson's proposed generic version of Fentora, a drug used to treat breakthrough pain in cancer patients, infringed four claims of U.S. Patent Number 6,264,981, prompting Watson to...
Fed. Circ. Affirms Cephalon Win In Generic Fentora IP Suit
To view the full article, take a free trial now.
